Tau N368 neonatal C-terminal epitope antigen peptide, Tau N368 neonatal C-terminal specific antibody, and their preparation methods and applications.

By preparing and purifying the Tau N368 neonatal C-terminal epitope antigen peptide and specific antibody, a sandwich immunoassay system was constructed, which solved the problem of low abundance of Tau protein cleavage fragments in blood and achieved highly sensitive quantitative detection and pathological assessment of Alzheimer's disease.

CN123106871APending Publication Date: 2026-11-17SHENZHEN UNIVERSITY OF ADVANCED TECHNOLOGY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611574313.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-10-12
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

In the current technology, the abundance of Tau protein and its cleavage fragments in blood is low, making it difficult to selectively identify Tau N368 cleavage fragments and achieve highly sensitive quantitative detection.

Method used

A Tau N368 neonatal C-terminal epitope antigen peptide was prepared, and the N-terminal amino acids were modified by acetylation. The peptide was then used to immunize mice with a carrier protein. Monoclonal antibodies that specifically recognize the Tau N368 neonatal C-terminal epitope were screened and purified. A sandwich immunoassay system was constructed, and quantitative analysis was performed using the SiMoA single-molecule detection platform.

Benefits of technology

It achieves highly sensitive quantitative detection of Tau N368 cleavage fragments in blood samples, can distinguish full-length Tau from other Tau forms, and provides early detection and assessment of Tau protein pathology related to Alzheimer's disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106871A_ABST
    Figure CN123106871A_ABST
Patent Text Reader

Abstract

This invention discloses a Tau N368 newly formed C-terminal epitope antigen peptide, a Tau N368 newly formed C-terminal specific antibody, and their preparation methods and applications, relating to the field of biomarker detection technology. The Tau N368 newly formed C-terminal epitope antigen peptide is used to prepare and / or screen antibodies or antigen-binding fragments thereof that specifically recognize the Tau N368 newly formed C-terminal epitope. The Tau N368 newly formed C-terminal specific antibody can specifically recognize the Tau N368 newly formed C-terminal epitope formed by the cleavage of the AEP after the Tau protein N368 site. A sandwich immunoassay system is constructed using the capture antibody and the Tau N368 newly formed C-terminal specific antibody to detect Tau N368 cleavage fragments in biological samples, enabling the detection and quantification of low-abundance Tau N368 cleavage fragments in plasma, serum, or biological samples containing Tau N368 cleavage fragments.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of biomarker detection technology, and in particular to a Tau N368 neonatal C-terminal epitope antigen polypeptide, a Tau N368 neonatal C-terminal specific antibody, and their preparation methods and applications. Background Technology

[0002] Alzheimer's disease (AD) is one of the most common neurodegenerative diseases. Its main pathological features include extracellular amyloid-β (Aβ) deposition, intracellular neurofibrillary tangles (NFTs) formed by the aggregation of abnormal Tau protein, synaptic dysfunction, and progressive neuronal loss.

[0003] In recent years, the development of blood biomarkers has significantly promoted the early detection and pathological assessment of Alzheimer's disease (AD). Currently, commonly used blood biomarkers mainly include the Aβ 42 / 40 ratio, phosphorylated Tau protein (e.g., p-tau181 and p-tau217), and total Tau protein (tTau). These biomarkers can provide information related to Aβ pathology, Tau protein phosphorylation, and neuronal damage, respectively. However, abnormal changes in Tau protein in AD and other neurodegenerative diseases are not only manifested by phosphorylation but also involve extensive proteolytic processes. Therefore, developing new detection methods for disease-related Tau protein cleavage products can provide molecular information different from traditional phosphorylated Tau biomarkers.

[0004] Asparagine endopeptidase (AEP), also known as delta-secretase, is a cysteine ​​protease that mediates proteolysis at specific asparagine residues. Previous studies have shown that AEP can cleave various proteins associated with neurodegenerative diseases, including amyloid precursor protein (APP), Tau protein, and α-synuclein. AEP cleaves Tau protein after the 368th asparagine residue (N368), producing a truncated Tau fragment with N368 as its N-terminus. This cleavage exposes N368, which was originally located within the intact Tau protein, as a newly exposed N-terminus, thus forming a new N-terminal epitope distinct from full-length Tau and Tau molecules that have not been cleaved at the N368 site.

[0005] Previous studies have shown that Tau N368-related indicators in cerebrospinal fluid (CSF) are correlated with neurofibrillary Tau pathology, Tau PET load, and cognitive function. However, compared with CSF, the abundance of Tau protein and its cleavage fragments in blood is lower, and there is a complex background of blood proteins. Therefore, selectively identifying Tau N368 cleavage fragments from blood samples and achieving highly sensitive quantitative detection remains a technical challenge.

[0006] Therefore, it is necessary to establish a method that can specifically identify the newly formed N-terminus after Tau N368 cleavage and has sufficient analytical sensitivity to detect low-abundance Tau N368 cleavage fragments in blood. Summary of the Invention

[0007] The main objective of this invention is to propose a Tau N368 neonatal C-terminal epitope antigen polypeptide, a Tau N368 neonatal C-terminal specific antibody, and its preparation method and application, aiming to solve the problems in the prior art of low abundance of Tau protein and its cleavage fragments in blood, and the difficulty in selectively recognizing Tau N368 cleavage fragments and achieving high-sensitivity quantitative detection.

[0008] To achieve the above objectives, the present invention proposes a Tau N368 neonatal C-terminal epitope antigen polypeptide, the amino acid sequence of which is shown in SEQ ID NO: 1, wherein the N-terminal amino acid of the Tau N368 neonatal C-terminal epitope antigen polypeptide is acetylated and the C-terminus is a free carboxyl group.

[0009] In one embodiment, the Tau N368 neonatal C-terminal epitope antigen peptide is used to prepare and / or screen for antibodies or antigen-binding fragments thereof that specifically recognize the Tau N368 neonatal C-terminal epitope.

[0010] In one embodiment, the Tau N368 neonatal C-terminal epitope antigen peptide is used to prepare and / or screen monoclonal antibodies that specifically recognize the Tau N368 neonatal C-terminal epitope.

[0011] In one embodiment, the Tau N368 neonatal C-terminal epitope is formed by asparagine endopeptidase cleaving the Tau protein after the N368 site, with N368 as the C-terminus.

[0012] This invention also provides a method for preparing a Tau N368 neonatal C-terminal specific antibody, comprising the following steps: The Tau N368 neonatal C-terminal epitope antigen polypeptide described above is coupled with a carrier protein to obtain a coupled antigen, wherein the carrier protein is selected from keyhole hemocyanin or bovine serum albumin. BALB / c mice were immunized with conjugated antigens. Serum from the immunized animals was collected, and the binding activity of serum to immune peptides was detected by indirect ELISA. The antibody titer was determined by serial dilution. After reaching the predetermined titer, spleen cells from the immunized animals were isolated. The spleen cells from the immunized animals were mixed with Sp2 / 0-Ag14 mouse myeloma cells in a certain proportion, and cell fusion was mediated by PEG. The cells were cultured to form hybridoma clones, and the culture supernatant of the hybridoma cells was collected. Antibodies in the culture supernatant of hybridoma cells were subjected to positive screening, reverse screening, and subcloning to obtain stable monoclonal hybridoma cell lines producing the target antibody. Stable monoclonal hybridoma cell lines were cultured, and the culture supernatant of the monoclonal hybridoma cell lines was collected, purified, and Tau N368 neonatal C-terminal specific antibody was obtained.

[0013] The present invention also provides a Tau N368 neonatal C-terminal specific antibody, which is prepared by the above method.

[0014] The present invention also provides a method for detecting Tau N368 lysates in biological samples, comprising the following steps: The capture antibody is immobilized on a solid support to obtain an immobilized capture antibody, which specifically recognizes an internal epitope of the Tau protein; The biological sample to be tested was incubated with the immobilized capture antibody to capture the Tau N368 cleavage fragment; After washing, add the above-mentioned Tau N368 neonatal C-terminal specific antibody to form a sandwich immune complex; After incubation with a signal labeling system in a sandwich immune complex, the mixture is washed, a fluorescent substrate matching the signal labeling system is added, and the detection signal is read through a detection platform. The detection signal value of the sample to be tested is converted into Tau N368 concentration, and the content of Tau N368 fragments in the sample to be tested is calculated according to the Tau N368 standard curve.

[0015] In one embodiment, the Tau N368 neonatal C-terminal specific antibody can be biotinylated using NHS-PEG4-Biotin; and / or, The biological sample to be tested is selected from at least one of plasma, serum, whole blood, cerebrospinal fluid, and other biological fluids containing Tau or Tau-derived molecules; and / or, The detection platform is selected from at least one of the following: ELISA detection platform, chemiluminescence immunoassay platform, electrochemiluminescence immunoassay platform, fluorescence immunoassay platform, digital immunoassay platform, and SiMoA single-molecule detection platform; and / or, The capture antibody is Anti-Tau antibody ab259552; and / or, The solid support is magnetic microspheres.

[0016] The present invention also provides a Tau N368 kit for a method of detecting Tau N368 lysates in biological samples, the Tau N368 kit comprising: Capture antibodies or antigen-binding fragments of Tau protein that recognize internal epitopes; Detection antibodies or their antigen-binding fragments that specifically recognize the newly formed C-terminal epitope of Tau N368; Tau N368 calibration standard; Quality control samples; Antibody-conjugated microbeads; Detection buffer; and Signal detection reagents.

[0017] The present invention also provides an application in the preparation of products for the pathological detection and / or evaluation of Tau protein associated with Alzheimer's disease.

[0018] The present invention provides a Tau N368 neonatal C-terminal epitope antigen polypeptide, which is used to prepare and / or screen antibodies or antigen-binding fragments that specifically recognize the Tau N368 neonatal C-terminal epitope. The acetylation modification only blocks the α-amino group of cysteine ​​and does not interfere with the coupling of the cysteine ​​side chain thiol group with the carrier protein, thus ensuring the effective preparation of the immunogen and thereby enabling the screening to obtain antibodies that specifically recognize the Tau N368 neonatal C-terminal epitope. Attached Figure Description

[0019] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on the structures shown in these drawings without creative effort.

[0020] Figure 1 This is a graph showing the selectivity verification results of the Tau N368 neonatal C-terminal specific monoclonal antibody in Example 2; Figure 2 This is a graph showing the detection levels of Tau N368 in different samples in the establishment and validation results of the immunoassay system for detecting Tau N368 cleavage fragments in Example 3. Figure 1 Figure A in the image shows immunoblotting and dot blot images. Figure 1Figure B in the figure is a Western blot experimental result. Figure 1 Figure C in the diagram represents the result of Rotenone processing. Figure 1 Figure D in the image shows the signal of Tau N368 neonatal C-terminal specific monoclonal antibody in AEP WT mice and AEP KO mice. Figure 1 Figure E in the image is a signal map of the C-terminus-specific monoclonal antibody in the neonatal TauN368 mice of Mapt- / - mice; Figure 3 Example 3: Establishment and validation results of an immunoassay system for detecting Tau N368 cleavage fragments, showing the expression of Tau N368 and related proteins; Figure 4 Example 4 shows the results of establishing a high-sensitivity detection method for Tau N368 based on single-molecule array (SiMoA) technology.

[0021] The realization of the objective, functional features and advantages of the present invention will be further explained in conjunction with the embodiments and with reference to the accompanying drawings. Detailed Implementation

[0022] To make the objectives, technical solutions, and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. Where specific conditions are not specified in the embodiments, conventional conditions or conditions recommended by the manufacturer shall apply. Where the manufacturers of reagents or instruments are not specified, they are all conventional products that can be purchased commercially. Furthermore, the meaning of "and / or" throughout the text includes three parallel solutions; for example, "A and / or B" includes solution A, or solution B, or a solution where both A and B are satisfied simultaneously. In addition, the technical solutions of the various embodiments can be combined with each other, but this must be based on the ability of those skilled in the art to implement them. When the combination of technical solutions is contradictory or cannot be implemented, it should be considered that such a combination of technical solutions does not exist and is not within the scope of protection claimed by the present invention. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0023] Asparagine endopeptidase (AEP), also known as delta-secretase, is a cysteine ​​protease that mediates proteolysis at specific asparagine residues. Previous studies have shown that AEP can cleave various proteins associated with neurodegenerative diseases, including amyloid precursor protein (APP), Tau protein, and α-synuclein. AEP cleaves Tau protein after the 368th asparagine residue (N368), producing a truncated Tau fragment with N368 as its N-terminus. This cleavage exposes N368, which was originally located within the intact Tau protein, as a newly exposed N-terminus, thus forming a new N-terminal epitope distinct from full-length Tau and Tau molecules that have not been cleaved at the N368 site.

[0024] Previous studies have shown that Tau N368-related indicators in cerebrospinal fluid (CSF) are correlated with neurofibrillary Tau pathology, Tau PET load, and cognitive function. However, compared with CSF, the abundance of Tau protein and its cleavage fragments in blood is lower, and there is a complex background of blood proteins. Therefore, selectively identifying Tau N368 cleavage fragments from blood samples and achieving highly sensitive quantitative detection remains a technical challenge.

[0025] In view of this, the present invention provides a Tau N368 neonatal C-terminal epitope antigen polypeptide, the amino acid sequence of which is shown in SEQ ID NO: 1CITHVPGGGN, wherein the N-terminal amino acid of the Tau N368 neonatal C-terminal epitope antigen polypeptide is acetylated and the C-terminus is a free carboxyl group, as shown in Ac-CITHVPGGGN-OH.

[0026] In the technical solution of the present invention, the amino acid sequence of the Tau N368 neonatal C-terminal epitope antigen polypeptide is shown in SEQ ID NO:1, and the sequence is CITHVPGGGN; the N-terminal amino acid of the Tau N368 neonatal C-terminal epitope antigen polypeptide is acetylated and the free carboxyl group is retained at the C-terminus to obtain Ac-CITHVPGGGN-OH. The C-terminus retains a free carboxyl group to mimic the natural nascent C-terminal chemical structure formed after asparagine endopeptidase cleaves the Tau protein at site N368. This free carboxyl group is a key component of the target epitope, ensuring that the antibodies obtained after immunization specifically recognize the pathological fragments of Tau produced by enzyme digestion in biological samples, distinguishing them from the full-length Tau protein. Acetylation blocking of the N-terminus of the peptide avoids the generation of non-specific antibodies against the artificial N-terminal amino group of the peptide, allowing the immune response to focus on the nascent C-terminal epitope. It also improves the stability of the peptide against aminopeptidase degradation. Furthermore, this acetylation modification only blocks the α-amino group of cysteine, without interfering with the coupling of the cysteine ​​side chain thiol group to the carrier protein, ensuring the effective preparation of the immunogen, and thus enabling the screening to obtain antibodies that specifically recognize the nascent C-terminal epitope of Tau N368.

[0027] In some embodiments of the present invention, the Tau N368 neonatal C-terminal epitope antigen polypeptide is used to prepare and / or screen antibodies or antigen-binding fragments thereof that specifically recognize the Tau N368 neonatal C-terminal epitope.

[0028] It is understandable that the Tau N368 neonatal C-terminal epitope antigenic peptide Ac-CITHVPGGGN-OH mimics the N368 neonatal C-terminal epitope formed after Tau protein is cleaved at the N368 site by AEP. This epitope is not present in full-length Tau. Immunizing animals with this peptide and combining it with forward and reverse screening can yield antibodies that preferentially recognize the Tau N368 cleavage fragment and have low binding signals to full-length Tau and other forms of Tau. Therefore, this Tau N368 neonatal C-terminal epitope antigenic peptide can be used to prepare and / or screen antibodies or antigen-binding fragments that specifically recognize the Tau N368 neonatal C-terminal epitope.

[0029] In some embodiments of the present invention, the Tau N368 neonatal C-terminal epitope antigen polypeptide is used to prepare and / or screen monoclonal antibodies that specifically recognize the Tau N368 neonatal C-terminal epitope.

[0030] It is understandable that the Tau N368 neonatal C-terminal epitope antigenic peptide Ac-CITHVPGGGN-OH mimics the N368 neonatal C-terminal epitope formed after Tau protein is cleaved at the N368 site by AEP. This epitope is not present in full-length Tau. By conjugating this peptide with keyhole hemocyanin to immunize BALB / c mice, and then performing cell fusion, positive selection, reverse selection, and limiting dilution subcloning, a hybridoma cell line that stably secretes a single antibody can be obtained. This line can then be used to prepare and / or screen for monoclonal antibodies that specifically recognize the Tau N368 neonatal C-terminal epitope.

[0031] In some embodiments of the present invention, the Tau N368 nascent C-terminal epitope is formed by asparagine endopeptidase after cleavage of the Tau protein at the N368 site, with N368 as the C-terminus.

[0032] It is understandable that the Tau N368 neonatal C-terminal epitope is formed by asparagine endopeptidase cleaving the Tau protein after the N368 site. The cleavage makes N368, which was originally located inside the intact Tau, become a newly exposed C-terminus, thus forming a neonatal C-terminal epitope with N368 as the C-terminus, which is different from the full-length Tau and Tau molecules that have not been cleaved at the N368 site.

[0033] This invention provides a method for preparing a Tau N368 neonatal C-terminal specific antibody, comprising the following steps: The above-mentioned Tau N368 neonatal C-terminal epitope antigen polypeptide is coupled with a carrier protein to obtain a coupled antigen, wherein the carrier protein is selected from keyhole hemocyanin or bovine serum albumin. BALB / c mice were immunized with conjugated antigens. Serum from the immunized animals was collected, and the binding activity of serum to immune peptides was detected by indirect ELISA. The antibody titer was determined by serial dilution. After reaching the predetermined titer, spleen cells from the immunized animals were isolated. The spleen cells from the immunized animals were mixed with Sp2 / 0-Ag14 mouse myeloma cells in a certain proportion, and cell fusion was mediated by PEG. The cells were cultured to form hybridoma clones, and the culture supernatant of the hybridoma cells was collected. Antibodies in the culture supernatant of hybridoma cells were subjected to positive screening, reverse screening, and subcloning to obtain stable monoclonal hybridoma cell lines producing the target antibody. Stable monoclonal hybridoma cell lines were cultured, and the culture supernatant of the monoclonal hybridoma cell lines was collected, purified, and Tau N368 neonatal C-terminal specific antibody was obtained.

[0034] Understandably, the Tau N368 neonatal C-terminal epitope antigen peptide Ac-CITHVPGGGN-OH is conjugated with keyhole hemocyanin or bovine serum albumin to obtain a conjugated antigen. BALB / c mice are immunized with this keyhole hemocyanin-conjugated antigen. Serum is collected after basal and booster immunizations, and the binding activity of the serum to the immune peptide is detected by indirect ELISA to determine the antibody titer. After reaching the predetermined titer, spleen cells are separated and mixed with Sp2 / O-Ag14 mouse myeloma cells in a specific ratio. Cell fusion is mediated by PEG, and hybridoma clones are cultured and the culture supernatant is collected. Subsequently, positive selection is performed using the BSA-conjugated antigen or recombinant Tau N368 protein. Positive selection ensures that the obtained antibody can bind to the Tau N368 cleavage fragment, confirming that the antibody has anti-Tau N368 activity. The binding ability of the newly formed C-terminal epitope N368 was assessed. Then, reverse screening was performed using full-length Tau, Tau fragments other than TauN368, and Tau proteins or peptides without the newly formed C-terminus N368 to exclude non-specific antibodies recognizing intact Tau or other Tau forms. Subcloning was performed using limiting dilution, and repeated forward and reverse screening were conducted to obtain a stable monoclonal hybridoma cell line secreting the target antibody. After expansion culture, the culture supernatant was collected, purified by Protein A or Protein G affinity chromatography, and antibody purity and antigen-binding activity were evaluated using SDS-PAGE, ELISA, and Western blot to finally obtain the Tau N368 newly formed C-terminal specific antibody.

[0035] The present invention also provides a Tau N368 neonatal C-terminal specific antibody, which is prepared by the above method.

[0036] Understandably, the Tau N368 neonatal C-terminal specific antibody preferentially recognizes the neonatal C-terminal epitope formed after Tau protein is cleaved at the N368 site by AEP, thereby distinguishing the Tau N368 cleavage fragment from full-length Tau and other Tau forms. This antibody can be used as a detection antibody to construct a sandwich immunoassay system with a capture antibody that recognizes Tau internal epitopes. A detection signal is only generated when the analyte molecule simultaneously possesses both a Tau internal epitope and a neonatal N368 C-terminus, achieving selective detection. Furthermore, combining this system with the SiMoA single-molecule detection platform enables highly sensitive quantitative detection of low-abundance Tau N368 cleavage fragments in plasma or serum. In addition, this antibody can also be used for antibody screening and evaluation, as well as for the detection and assessment of Tau protein pathology related to Alzheimer's disease.

[0037] This invention provides a method for detecting Tau N368 lysates in biological samples, comprising the following steps: The capture antibody is immobilized on a solid support to obtain an immobilized capture antibody, which specifically recognizes an internal epitope of the Tau protein; The biological sample to be tested was incubated with the immobilized capture antibody to capture the Tau N368 cleavage fragment; After washing, add Tau N368 neonatal C-terminal specific antibody to form a sandwich immune complex; After incubation with a signal labeling system in a sandwich immune complex, the mixture is washed, a fluorescent substrate matching the signal labeling system is added, and the detection signal is read through a detection platform. The detection signal value of the sample to be tested is converted into Tau N368 concentration, and the content of Tau N368 fragments in the sample to be tested is calculated according to the Tau N368 standard curve.

[0038] Understandably, the capture antibody specifically recognizes the internal epitope of Tau protein, binding to various Tau molecules in the sample, including the Tau N368 cleavage fragment, and immobilizing them on a solid-phase support. The detection antibody is a Tau N368 nascent C-terminal specific antibody, recognizing only the nascent C-terminal epitope formed after Tau protein is cleaved at the N368 site by an AEP. This epitope is not present in full-length Tau or Tau molecules not cleaved at the N368 site. Therefore, only when the analyte simultaneously possesses both the Tau internal epitope recognized by the capture antibody and the nascent C-terminus of N368 can a complete sandwich immune complex be formed and a detection signal generated, thereby achieving selective detection of the Tau N368 cleavage fragment and effectively distinguishing full-length Tau from other Tau forms. Subsequently, the antibody binding event is converted into a readable signal through a signal labeling system and a matching fluorescent substrate, and the signal is read using a detection platform. The signal value is then converted into a concentration based on the Tau N368 standard curve, thus enabling the quantitative determination of the Tau N368 cleavage fragment content in the analyte sample. In one embodiment, the detection platform is a SiMoA single-molecule detection platform, which can achieve high-sensitivity detection of low-abundance Tau N368 cleavage fragments in plasma or serum.

[0039] In some embodiments of the present invention, the Tau N368 neonatal C-terminal specific antibody can be biotinylated using NHS-PEG4-Biotin; and / or, The biological sample to be tested is selected from at least one of plasma, serum, whole blood, cerebrospinal fluid, and other biological fluids containing Tau or Tau-derived molecules; and / or, The detection platform is selected from at least one of the following: ELISA detection platform, chemiluminescence immunoassay platform, electrochemiluminescence immunoassay platform, fluorescence immunoassay platform, digital immunoassay platform, and SiMoA single-molecule detection platform; and / or, The capture antibody is Anti-Tau antibody ab259552; and / or, The solid support is magnetic microspheres.

[0040] It is understood that the Tau N368 neonatal C-terminal specific antibody can be biotinylated using NHS-PEG4-Biotin to bind to the streptavidin-β-galactosidase signaling system. The test biological sample can be selected from plasma, serum, whole blood, cerebrospinal fluid, or other biological fluids containing Tau or Tau-derived molecules. As long as the sample contains Tau or Tau-derived molecules, it can be detected using the method of this invention, especially suitable for detecting low-abundance Tau N368 cleavage fragments in blood samples. The detection platform can be selected from ELISA, chemiluminescent immunoassay, electrochemiluminescent immunoassay, fluorescence immunoassay, digital immunoassay, or the SiMoA single-molecule detection platform. Any platform capable of reading the signal generated by the sandwich immune complex is suitable, with the SiMoA platform preferred for high-sensitivity quantitative detection. In one specific embodiment, the capture antibody is Anti-Tauantibody ab259552, and the solid-phase carrier is magnetic microbeads. After the capture antibody is coupled to the magnetic microbeads and incubated with the sample, biotinylated Tau... The N368 detection antibody forms a sandwich immune complex, and a detection signal is generated by SPG and fluorescent substrate. Finally, the content of Tau N368 cleavage fragment in the sample is calculated according to the Tau N368 standard curve.

[0041] The present invention also provides a Tau N368 kit for a method of detecting Tau N368 lysates in biological samples, the Tau N368 kit comprising: Capture antibodies or antigen-binding fragments of Tau protein that recognize internal epitopes; Detection antibodies or their antigen-binding fragments that specifically recognize the newly formed C-terminal epitope of Tau N368; Tau N368 calibration standard; Quality control samples; Antibody-conjugated microbeads; Detection buffer; and, Signal detection reagents.

[0042] It is understood that the Tau N368 kit provided by this invention comprises a capture antibody that recognizes an internal epitope of Tau protein, a detection antibody that specifically recognizes a newly formed C-terminal epitope of Tau N368, a Tau N368 calibration standard, a quality control sample, antibody-conjugated beads, a detection buffer, and a signal detection reagent. The capture antibody is used to recognize an internal epitope of Tau and enrich Tau molecules in the sample; the detection antibody recognizes only the newly formed C-terminal epitope of Tau N368, thereby forming a sandwich immune complex with the capture antibody for selective detection; the calibration standard is used to establish a standard curve and convert signal values ​​into Tau N368 concentration; the quality control sample is used to monitor the stability and reliability of the detection process; the antibody-conjugated beads serve as a solid-phase carrier for the capture antibody, facilitating washing and separation and supporting single-molecule detection of SiMoA; the detection buffer provides a suitable reaction environment and reduces non-specific background; the signal detection reagent is used to convert antigen-antibody binding events into a readable signal, and in a preferred embodiment includes streptavidin-β-galactosidase and a fluorescent substrate. The above components work together to achieve highly sensitive quantitative detection of Tau N368 lysate fragments in biological samples containing Tau N368 lysate fragments, such as plasma, serum, whole blood, and cerebrospinal fluid.

[0043] The present invention also provides an application in the preparation of products for the pathological detection and / or evaluation of Tau protein associated with Alzheimer's disease.

[0044] It is understood that the Tau N368 neonatal C-terminal epitope antigen peptide provided by this invention can mimic the N368 neonatal C-terminal epitope formed after Tau protein is cleaved at the N368 site by AEP, and can be used to prepare and / or screen antibodies that specifically recognize this epitope; the detection method utilizes a sandwich immunoassay system constructed with a capture antibody that recognizes internal Tau epitopes and a Tau N368 neonatal C-terminal specific detection antibody, which can selectively detect Tau N368 cleavage fragments in biological samples; the kit contains the antibodies, standards, buffers, and signal reagents required for implementing the detection method; since the Tau N368 cleavage fragment is a characteristic product of AEP-mediated Tau protein pathological processing, and its level is closely related to Tau protein pathology associated with Alzheimer's disease, the above-mentioned Tau N368 neonatal C-terminal epitope antigen peptide, detection method, and kit can be used to prepare products for the detection and / or evaluation of Tau protein pathology associated with Alzheimer's disease, providing new molecular information for the early detection and pathological evaluation of AD.

[0045] The technical solution of the present invention will be further described in detail below with reference to specific embodiments and accompanying drawings. It should be understood that the following embodiments are only used to explain the present invention and are not intended to limit the present invention.

[0046] Example 1 The preparation method of the Tau N368 neonatal C-terminal epitope antigen peptide includes the following steps: This embodiment uses the fluorenemethyloxycarbonyl (Fmoc) solid-phase peptide synthesis method to prepare the nascent C-terminal epitope antigen peptide of Tau N368. Its amino acid sequence is CITHVPGGGN, with the N-terminus acetylated and the C-terminus retaining a free carboxyl group, denoted as Ac-CITHVPGGGN-OH. The specific preparation steps are as follows: (1) Resin preparation Pre-loaded Fmoc-Asn(Trt)-Wang resin was selected as the solid-phase synthesis support. Resin was weighed according to a synthesis scale of 0.1 mmol, and N,N-dimethylformamide (DMF) was added. The resin was soaked at room temperature for 30 min to allow it to fully swell. DMF was removed by filtration and the solution was set aside.

[0047] (2) Removal of Fmoc protecting groups Add a DMF solution containing 20% ​​piperidine to the swollen resin, react at room temperature for 5 min, filter to remove the reaction solution, then add fresh 20% piperidine / DMF solution and react for 10 min. After the reaction is complete, wash the resin three times with DMF to remove residual deprotecting agent.

[0048] (3) Stepwise coupling of amino acids Following the order of the target peptide from C-terminus to N-terminus, Gly, Gly, Gly, Pro, Val, His, Thr, Ile, and Cys were coupled sequentially. In each coupling reaction, 4 molar amounts of Fmoc protecting amino acids, 4 molar amounts of HATU, and 8 molar amounts of N,N-diisopropylethylamine (DIPEA) relative to the resin loading were added, and the reaction was carried out at room temperature with shaking for 60 min using DMF as the solvent. After each coupling, the reaction solution was filtered off, the resin was washed 5 times with DMF, and the Fmoc protecting group was removed according to step (2) before continuing to couple the next amino acid. Cysteine ​​was protected with Fmoc-Cys(Trt)-OH, histidine with Fmoc-His(Trt)-OH, and threonine with Fmoc-Thr(tBu)-OH to protect the corresponding side chain groups. The above operation was repeated until the assembly of the entire amino acid sequence of CITHVPGGGN was completed.

[0049] (4) N-terminal acetylation of peptide After coupling the last cysteine ​​residue and removing its Fmoc protecting group, a DMF solution containing acetic anhydride and DIPEA was added to the resin, with a molar ratio of acetic anhydride to resin loading of 10:1. The mixture was shaken at room temperature for 30 min to induce acetylation of the N-terminal amino group of the peptide. After the reaction, the resin was washed sequentially with DMF and dichloromethane to remove unreacted acetic anhydride and other reagents.

[0050] (5) Peptide cleavage and side chain deprotection A cleavage solution consisting of trifluoroacetic acid (TFA), triisopropylsilane (TIS), and ultrapure water in a volume ratio of 95:2.5:2.5 was added to the synthesized peptide resin. The reaction was carried out at room temperature with shaking for 2 h to cleave the peptide from the resin and remove the protecting groups of the amino acid side chains. After the reaction, the resin was removed by filtration, and the filtrate was collected. Approximately 10 times the volume of pre-cooled anhydrous diethyl ether was added to the filtrate to precipitate the crude peptide. The precipitate was collected by centrifugation and washed three times with pre-cooled anhydrous diethyl ether to remove residual cleavage reagents and organic impurities, yielding the crude peptide.

[0051] (6) Peptide purification The crude peptide was dissolved in ultrapure water or a suitable acetonitrile-water mixture, filtered through a 0.22 μm filter membrane, and purified by reversed-phase high-performance liquid chromatography (RP-HPLC). A C18 reversed-phase column was used. Mobile phase A was ultrapure water containing 0.1% TFA, and mobile phase B was acetonitrile containing 0.1% TFA. Gradient elution was used to separate the peptides. The elution peaks corresponding to the target peptides were collected, the target fractions were combined, and lyophilized to obtain the purified Ac-CITHVPGGGN-OH peptide.

[0052] (7) Identification and preservation of polypeptides The purity of the obtained peptides was determined by analytical HPLC, and its molecular weight was identified by mass spectrometry (MS), confirming that the obtained product was consistent with the theoretical molecular weight of Ac-CITHVPGGGN-OH. The purified peptides were lyophilized and then aliquoted and stored at [location missing]. Store at 20°C, avoiding repeated freeze-thaw cycles. The resulting peptide contains cysteine ​​residues at the N-terminus for subsequent carrier protein conjugation, and asparagine (Asn, N) at the C-terminus as the terminal amino acid, which is used to mimic the newly formed C-terminal epitope of Tau protein after proteolytic cleavage at the N368 site. This can be used for subsequent antigen conjugation, animal immunization, and the preparation of Tau N368-specific antibodies.

[0053] Example 2 Preparation and selectivity validation of Tau N368 neonatal C-terminal specific monoclonal antibody The Tau N368 neonatal C-terminal epitope antigen peptide Ac-CITHVPGGGN-OH was conjugated with keyhole hemocyanin (KLH) and bovine serum albumin (BSA), respectively. The KLH-conjugated antigen was used for immunization, and the BSA-conjugated antigen was used for ELISA screening. Female BALB / c mice aged 6-8 weeks were selected and primarily immunized with KLH-conjugated antigen at a dose of 100 μg per mouse, emulsified with Freund's complete adjuvant and injected subcutaneously at multiple sites. Booster immunizations were performed every 2 weeks with Freund's incomplete adjuvant emulsified antigen at a dose of 50 μg per mouse, for a total of 3 booster immunizations. Blood was collected 7 days after the last booster immunization, serum was separated, and enzyme-linked immunosorbent assay (ELISA) plates were coated with BSA-conjugated antigen. Serum antibody titers were detected by indirect ELISA. Once the predetermined titer was reached, the mice were induced into cell fusion. Spleen cells from immunized mice were aseptically isolated and mixed with Sp2 / O-Ag14 mouse myeloma cells at an 8:1 ratio. Cell fusion was mediated using 50% (w / v) PEG, and the cells were transferred to a HAT selection culture system, aliquoted into 96-well plates, and cultured at 37°C and 5% CO2 to allow the fused cells to form hybridoma clones. The supernatant of the hybridoma cell culture was collected, and positive selection antigens were obtained by ELISA using BSA-APP / TauN368 antigen peptide, Tau N368 newly formed C-terminal epitope antigen peptide, or recombinant TauN368 protein. The wells that could recognize TauN368 were selected by ELISA. Subsequently, reverse selection was performed using full-length Tau, Tau cleavage fragments other than Tau N368, and Tau protein or peptides without the newly formed C-terminus of N368. Clones with high binding signals to the newly formed C-terminus of TauN368 and low binding signals to full-length Tau and other forms of Tau were preferentially retained. Subcloning was performed on positive wells using limiting dilution, and forward and reverse screening were repeated until a stable monoclonal hybridoma cell line was obtained.

[0054] Stable monoclonal hybridoma cell lines were expanded and cultured, and the culture supernatant was collected to obtain antibody stock solution. Protein A or Protein G affinity chromatography was used for purification, and the purity and antigen-binding activity of the antibody were evaluated by SDS-PAGE, ELISA and Western blot. Finally, Tau N368 neonatal C-terminal specific monoclonal antibody was obtained.

[0055] The selectivity of the obtained Tau N368 neonatal C-terminal specific monoclonal antibody was determined by... Figure 1 The experiments shown verified that in both immunoblotting and dot blotting, the primary antibody was diluted 1:10000 and incubated overnight at 4°C. The antigen loading gradients for dot blotting were 300 ng, 30 ng, 3 ng, 300 pg, and 30 pg. The results indicated that the Tau N368 neonatal C-terminal specific antibody produced a significant concentration-dependent signal for the N368 antigen, remaining detectable even at a low loading of 30 pg, while significantly reducing the signal for 4R2N. Figure 1(Figure A in the figure); In the Western blot experiment, the primary antibody dilution ratio was 1:5000 to 1:10000, and the incubation was carried out overnight at 4°C. The loading volume of the lysis buffer was 40-100 μg; The Tau N368 nascent C-terminal specific monoclonal antibody only recognizes GST-Tau N368 and not GST-Tau FL ( Figure 1 Figure B in the figure); In samples treated with Rotenone, the signal of the Tau N368 nascent C-terminus-specific monoclonal antibody increased with increasing Rotenone concentration (Figure B in the figure). Figure 1 (Figure C in the figure); In AEP WT mice, the signal of Tau N368 neonatal C-terminal specific monoclonal antibody increases over time ( Figure 1 (Figure D in the diagram), while significantly reduced in AEP KO mice (Figure D in the diagram). Figure 1 (Figure D in the diagram); Tau N368 neonatal C-terminal specific monoclonal antibody signal was detectable in Mapt+ / + mice, but no signal was detected in Mapt- / - mice (Figure D in the diagram). Figure 1 (Figure E in the diagram).

[0056] like Figure 1 The results demonstrate that the obtained Tau N368 monoclonal antibody can selectively recognize the newly formed C-terminal epitope of Tau N368 and has high sensitivity.

[0057] Example 3 Establishment of the Tau N368 ELISA detection system and its application in mouse samples To establish a specific quantitative detection method for the Tau N368 cleavage fragment, a double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) was used. The anti-Tau protein antibody (Abcam, ab259552) was used as the capture antibody, and the Tau N368 specific monoclonal antibody was used as the detection antibody. A standard curve was established using recombinant Tau N368 protein.

[0058] The specific testing steps are as follows: (1) Antibody coating: Dilute the capture antibody to 1 μg / mL with carbonate coating buffer (pH 9.6), add 100 μL to each well, and incubate overnight at 4°C. Discard the coating solution and wash three times with PBST.

[0059] (2) Blocking: Add 200 μL of PBS blocking solution containing 1% BSA to each well, incubate at 37°C for 1 h, and then wash 3 times with PBST.

[0060] (3) Sample processing and incubation: Brain tissue, cerebrospinal fluid, and blood samples were collected from Tg-AD and wild-type (WT) mice. Brain tissue was homogenized, lysed, and centrifuged to collect the protein supernatant; cerebrospinal fluid was centrifuged to remove impurities and the supernatant was collected; blood was centrifuged to obtain plasma or serum. Samples were appropriately diluted according to the detection requirements. Simultaneously, recombinant Tau N368 protein was prepared into a series of concentration standards. 100 μL of standard or test sample was added to each well, and the mixture was incubated at 37°C for 1 h, followed by washing three times with PBST.

[0061] (4) Antibody incubation: Add 100 μL of appropriately diluted Tau N368 specific monoclonal antibody to each well and incubate at 37°C for 1 h to allow it to bind to the captured Tau N368 lysate fragments. Then wash three times with PBST.

[0062] (5) Signal detection: Add 100 μL of HRP-labeled secondary antibody that matches the detection antibody to each well, incubate at 37°C for 30 min, and then wash 5 times with PBST. Add 100 μL of TMB chromogenic solution to each well, react in the dark for 10–15 min, add 50 μL of 1M sulfuric acid to stop the reaction, and use an ELISA reader to detect the absorbance value at 450 nm.

[0063] (6) Calculation of results: A standard curve was established based on the concentration of recombinant Tau N368 standard and the corresponding absorbance value. The content of Tau N368 in different samples was calculated and converted accordingly based on the sample dilution factor and protein concentration.

[0064] To further validate the Tau N368 detection results, Western blot analysis was performed on the expression of related proteins in the brain tissues of Tg-AD and WT mice. Extracted brain tissue proteins were separated by SDS-PAGE electrophoresis and transferred to a PVDF membrane. Detection was performed using a Tau N368 neonatal C-terminal specific monoclonal antibody, anti-Tau 5, anti-AEP, anti-APP, and anti-Tubulin antibodies, respectively. Protein bands were visualized using corresponding HRP-labeled secondary antibodies and chemiluminescence systems, with Tubulin used as an internal control for sample loading.

[0065] Figure 2 and Figure 3 The results of this ELISA system in brain tissue, cerebrospinal fluid and blood samples from Tg-AD and WT mice were presented. Figure 2 The bar chart shows the detection level of Tau N368 in different samples. Figure 3 The Western blot panel further demonstrated the expression of Tau N368 and related proteins.

[0066] like Figure 2As shown, the established ELISA immunoassay can detect Tau N368 in brain tissue and body fluid samples from Tg-AD and WT mice, providing experimental basis for the specific detection and quantitative analysis of Tau N368 cleavage fragments.

[0067] Example 4 Establishment of a single-molecule-level SiMoA detection method at the N368 site of Tau protein Anti-Tau antibody ab259552, which recognizes internal epitopes of the Tau protein, was used as the capture antibody. Approximately 60 μg of the capture antibody was mixed with approximately 4.2 × 10⁻⁶ g of Tau protein. 8 The magnetic microbeads were coupled (300 μL system), and the working final concentration of the capture antibody-conjugated microbeads was adjusted to approximately 2 × 10⁻⁶. 7 beads / mL; TauN368 neonatal C-terminal specific monoclonal antibody was biotinylated using NHS-PEG4-Biotin. Approximately 15 μg (3 μL) of biotin was used to treat approximately 100 μg of detection antibody. The final working concentration of the biotinylated detection antibody was adjusted to approximately 5 μg / mL. During the detection process, the sample to be tested or the TauN368 standard is incubated with capture antibody-conjugated microbeads and TauN368-specific detection antibody for about 2 hours to capture the TauN368 lysate fragments and form a sandwich immune complex; the incubation conditions are 25°C and 800 rpm. After washing to remove unbound components, approximately 150 pM streptavidin-β-galactosidase (SβG) was added and incubated for about 10 minutes for signal labeling. The incubation conditions were 25°C and 800 rpm. After signal labeling, a fluorescent substrate matching SβG was added, and the microbeads were loaded into a SiMoA fly-volume microporous array. Detection signals were obtained via single-molecule digital signal reading. Standard curves were established using a series of concentrations of recombinant TauN368. Figure 4 The results showed that the method produced a stable concentration-dependent detection signal for TauN368 in a low concentration range, with a standard curve R²=0.99, indicating high analytical sensitivity and meeting the detection requirements for low-abundance TauN368 cleavage fragments in blood.

[0068] The above results demonstrate that by combining the TauN368 neonatal C-terminus-specific recognition system with SiMoA single-molecule detection technology, a highly sensitive quantitative detection method for blood TauN368 lysate fragments can be established.

[0069] The above are merely preferred embodiments of the present invention and do not limit the patent scope of the present invention. Various modifications and variations can be made to the present invention by those skilled in the art. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the patent protection scope of the present invention.

Claims

1. A Tau N368 neonatal C-terminal epitope antigen polypeptide, characterized in that, The amino acid sequence of the Tau N368 neonatal C-terminal epitope antigen polypeptide is shown in SEQ ID NO:

1. The N-terminal amino acid of the Tau N368 neonatal C-terminal epitope antigen polypeptide is acetylated, and the C-terminus is a free carboxyl group.

2. The Tau N368 neonatal C-terminal epitope antigen polypeptide as described in claim 1, characterized in that, The Tau N368 neonatal C-terminal epitope antigen peptide is used to prepare and / or screen antibodies or antigen-binding fragments thereof that specifically recognize the Tau N368 neonatal C-terminal epitope.

3. The Tau N368 neonatal C-terminal epitope antigen polypeptide as described in claim 1, characterized in that, The Tau N368 neonatal C-terminal epitope antigen peptide is used to prepare and / or screen monoclonal antibodies that specifically recognize the Tau N368 neonatal C-terminal epitope.

4. The Tau N368 neonatal C-terminal epitope antigen polypeptide as described in claim 2 or 3, characterized in that, The newly formed C-terminal epitope of TauN368 is formed by asparagine endopeptidase after cleavage of the Tau protein at the N368 site, with N368 as the C-terminus.

5. A method for preparing a Tau N368 neonatal C-terminal specific antibody, characterized in that, Includes the following steps: The Tau N368 neonatal C-terminal epitope antigen polypeptide according to any one of claims 1-4 is coupled with a carrier protein to obtain a coupled antigen, wherein the carrier protein is selected from keyhole hemocyanin or bovine serum albumin. BALB / c mice were immunized with conjugated antigens. Serum from the immunized animals was collected, and the binding activity of serum to immune peptides was detected by indirect ELISA. The antibody titer was determined by serial dilution. After reaching the predetermined titer, spleen cells from the immunized animals were isolated. The spleen cells from the immunized animals were mixed with Sp2 / 0-Ag14 mouse myeloma cells in a certain proportion, and cell fusion was mediated by PEG. The cells were cultured to form hybridoma clones, and the culture supernatant of the hybridoma cells was collected. Antibodies in the culture supernatant of hybridoma cells were subjected to positive screening, reverse screening, and subcloning to obtain stable monoclonal hybridoma cell lines that secrete target antibodies. Stable monoclonal hybridoma cell lines were cultured, and the culture supernatant of the monoclonal hybridoma cell lines was collected, purified, and TauN368 neonatal C-terminal specific antibody was obtained.

6. A Tau N368 neonatal C-terminal specific antibody, characterized in that, It was prepared by the method for preparing the Tau N368 neonatal C-terminal specific antibody as described in claim 5.

7. A method for detecting Tau N368 lysates in biological samples, characterized in that, Includes the following steps: The capture antibody is immobilized on a solid support to obtain an immobilized capture antibody, which specifically recognizes an internal epitope of the Tau protein; The biological sample to be tested was incubated with the immobilized capture antibody to capture the Tau N368 cleavage fragment; After washing, the Tau N368 neonatal C-terminal specific antibody as described in claim 6 is added to form a sandwich immune complex; After incubation with a signal labeling system in a sandwich immune complex, the mixture is washed, a fluorescent substrate matching the signal labeling system is added, and the detection signal is read through a detection platform. The detection signal value of the sample to be tested was converted into Tau N368 concentration, and the content of Tau N368 fragments in the sample to be tested was calculated by using the Tau N368 standard curve.

8. The method for detecting Tau N368 lysates in biological samples according to claim 7, characterized in that, The Tau N368 neonatal C-terminal specific antibody according to claim 6 can be biotinylated using NHS-PEG4-Biotin; and / or The biological sample to be tested is selected from at least one of plasma, serum, whole blood, cerebrospinal fluid, and other biological fluids containing Tau or Tau-derived molecules; and / or, The detection platform is selected from at least one of the following: ELISA detection platform, chemiluminescence immunoassay platform, electrochemiluminescence immunoassay platform, fluorescence immunoassay platform, digital immunoassay platform, and SiMoA single-molecule detection platform; and / or, The capture antibody is Anti-Tau antibody ab259552; and / or, The solid support is magnetic microspheres.

9. A Tau N368 kit for implementing the method for detecting Tau N368 lysates in biological samples as described in claim 7, characterized in that, The Tau N368 reagent kit includes: Capture antibodies or antigen-binding fragments of Tau protein that recognize internal epitopes; Detection antibodies or their antigen-binding fragments that specifically recognize the newly formed C-terminal epitope of Tau N368; Tau N368 calibration standard; Quality control samples; Antibody-conjugated microbeads; Detection buffer; and, Signal detection reagents.

10. The use of the Tau N368 neonatal C-terminal epitope antigen peptide according to any one of claims 1-4 or the kit according to claim 9 in the preparation of products for pathological detection and / or evaluation of Tau protein associated with Alzheimer's disease.